Zidovudine and Lamivudine for HTLV-I-Associated Myelopathy
Author Information
Author(s): Graham P Taylor, Peter Goon, Yoshitaka Furukawa, Hannah Green, Anna Barfield, Angelina Mosley, Hirohisa Nose, Abdel Babiker, Peter Rudge, Koichiro Usuku, Mitsuhiro Osame, Charles R M Bangham, Jonathan N Weber
Primary Institution: Imperial College, London, UK
Hypothesis
Can combination therapy with zidovudine and lamivudine improve outcomes in patients with HTLV-I-associated myelopathy?
Conclusion
The study found no significant clinical improvement in patients with HTLV-I-associated myelopathy after treatment with zidovudine and lamivudine.
Supporting Evidence
- Six patients discontinued zidovudine during the study.
- No significant changes in clinical measures were observed between the treatment groups.
- Active therapy was associated with a decrease in CD8 and non-T lymphocyte counts.
Takeaway
The researchers wanted to see if two medicines could help people with a specific virus-related illness, but they didn't find any benefits.
Methodology
A randomised, double-blind, placebo-controlled trial over six months with 16 patients.
Limitations
The long history of the disease in participants may have led to irreversible nerve damage, affecting the results.
Participant Demographics
{"country":{"England":12,"Japan":4},"gender":{"male":5,"female":11},"ethnic_origin":{"Afro-Caribbean":10,"Indian":1,"Japanese":4,"Persian":1},"mean_age":57.4}
Statistical Information
P-Value
p=0.92
Statistical Significance
p=0.92
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website